A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 17 Feb 2019
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE Mono-1
- Sponsors Pfizer
- 08 Feb 2019 Planned End Date changed from 1 Mar 2019 to 29 Mar 2019.
- 08 Feb 2019 Planned primary completion date changed from 1 Mar 2019 to 29 Mar 2019.
- 02 Jan 2019 Planned End Date changed from 29 Mar 2019 to 1 Mar 2019.